new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib)
January 2013
You'll hear about a new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib).
Xeljanz is the first Janus kinase (JAK) inhibitor. Janus kinases are enzymes linked to inflammation in joints and other tissues.
It's not a first-line agent. It's for patients who have failed or can't tolerate methotrexate.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote